iGenomeDx Inc. Company Profile

Background

Overview

iGenomeDx Inc. is a molecular diagnostic laboratory based in San Antonio, Texas, specializing in pharmacogenomics and infectious disease testing. Established in 2016 by Dr. Niti Vanee and Dr. Pramod Mishra, the company leverages cutting-edge technologies to provide accurate, fast, and actionable genetic results, aiming to make precision medicine a reality for patients and healthcare providers in the Alamo Region.

Mission and Vision

The mission of iGenomeDx is to enhance decision-making for physicians, improve patient care, and reduce healthcare costs by offering reliable genetic and drug monitoring testing services. Their vision is to become the most trusted genetic testing and drug monitoring laboratory in San Antonio, focusing on precision diagnostics, scientific integrity, and excellent customer service.

Industry Significance

Operating within the biotechnology and healthcare sectors, iGenomeDx plays a crucial role in advancing personalized medicine. By providing comprehensive molecular diagnostic services, the company contributes to improved patient outcomes and supports healthcare providers in delivering tailored treatments.

Key Strategic Focus

Core Objectives

Precision Medicine: Delivering personalized healthcare solutions through genetic testing and drug monitoring.

Quality Assurance: Maintaining high standards of accuracy and reliability in diagnostic testing.

Customer Service: Providing exceptional support to healthcare providers and patients.

Areas of Specialization

Pharmacogenomics: Assessing how an individual's genetic makeup affects their response to medications.

Infectious Disease Testing: Detecting a wide range of infectious diseases using advanced molecular techniques.

Genetic Risk Assessment: Evaluating genetic predispositions to various health conditions.

Drug Monitoring: Ensuring optimal medication levels for patient safety and efficacy.

Key Technologies Utilized

Polymerase Chain Reaction (PCR): Amplifying DNA sequences for detection and analysis.

Liquid Chromatography-Mass Spectrometry (LCMS): Analyzing complex mixtures for precise measurement of substances.

Primary Markets Targeted

iGenomeDx primarily serves healthcare providers and patients in the San Antonio area, with plans to expand its services to broader regions. The company also collaborates with national and international partners to enhance its service offerings.

Financials and Funding

Funding History

Specific details regarding iGenomeDx's total funds raised and recent funding rounds are not publicly disclosed. The company has been recognized for its contributions to the healthcare sector, including being awarded the 2022 Minority-Owned Small Business of the Year by the U.S. Small Business Administration.

Notable Investors

Information about individual investors is not publicly available.

Utilization of Capital

While specific utilization details are not disclosed, the capital raised is likely directed towards expanding laboratory capabilities, enhancing service offerings, and supporting research and development initiatives.

Pipeline Development

Key Pipeline Candidates

CIZ1B Biomarker Test: iGenomeDx has been appointed as the first COLA-accredited and CLIA-certified laboratory to launch the CIZ1B blood test for early-stage lung cancer detection in the U.S.

Stages of Development

The CIZ1B test is in the pre-commercialization phase, with operational and quality systems being established to meet regulatory standards.

Target Conditions

The primary focus is on early-stage lung cancer detection.

Anticipated Milestones

The test is expected to be available to clinicians in the near future, following the completion of necessary validations and regulatory approvals.

Technological Platform and Innovation

Proprietary Technologies

CIZ1B Biomarker Assay: A non-invasive blood test developed for early lung cancer detection.

Significant Scientific Methods

Next-Generation Sequencing (NGS): Providing comprehensive genomic profiling for personalized medicine.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, the integration of advanced technologies suggests potential applications in data analysis and interpretation.

Leadership Team

Key Executives

Dr. Niti Vanee, Ph.D.: Co-Founder and CEO (Honorary). Dr. Vanee holds a Ph.D. in Integrative Life Sciences with a focus on Bioinformatics and Systems Biology from Virginia Commonwealth University. She is also an Adjunct Assistant Professor at the School of Nursing, UT Health San Antonio.

Dr. Pramod Mishra, Ph.D.: Co-Founder and COO. Dr. Mishra earned his Ph.D. in Microbiology & Immunology from UT Health San Antonio. Prior to iGenomeDx, he was an Assistant Professor of Research at UT San Antonio and Adjunct Faculty at UIW.

Competitor Profile

Market Insights and Dynamics

The molecular diagnostics market is experiencing significant growth, driven by advancements in personalized medicine and increasing demand for accurate and rapid diagnostic tests.

Competitor Analysis

GeneDx: Offers genetic testing services for rare and ultra-rare disorders, providing whole exome sequencing and deletion/duplication analysis.

Ambry Genetics: Provides comprehensive genetic testing services, including next-generation sequencing and array-based testing.

23andMe: A consumer genetics and research company offering direct-to-consumer genetic testing services.

Strategic Collaborations and Partnerships

iGenomeDx's collaboration with Cizzle Bio Inc. to launch the CIZ1B biomarker test exemplifies its strategic approach to expanding service offerings and entering new markets.

Operational Insights

iGenomeDx differentiates itself through its commitment to quality, rapid turnaround times, and personalized customer service, setting it apart from larger, less personalized laboratories.

Strategic Opportunities and Future Directions

Strategic Roadmap

Expansion of Service Offerings: Introducing new diagnostic tests and expanding into additional therapeutic areas.

Technological Advancements: Integrating advanced technologies to enhance testing capabilities and data analysis.

Geographical Expansion: Extending services beyond the San Antonio area to reach a broader patient population.

Opportunities for Expansion

The partnership with Cizzle Bio Inc. positions iGenomeDx to become a leader in early-stage lung cancer detection, opening avenues for further collaborations and market expansion.

Future Objectives

Leveraging current strengths, iGenomeDx aims to achieve its objectives by focusing on innovation, quality, and customer-centric services to meet the evolving needs of the healthcare industry.